OTC · Health care

Nika Pharmaceuticals, Inc (NIKA)

It posted a net loss of $78.1K. At June 30, 2026 it held $2.9K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Watch NIKA in 60 seconds

Price

$0.41

0.00% on the day · September 25, 2026

52-week range $0.20 to $0.98

Market cap

$431.2M

What Nika Pharmaceuticals, Inc does

Nika Pharmaceuticals, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker NIKA.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$76.4K	-$76.4K	$0.00	n/a
2024	$0	-$95.8K	-$95.8K	$0.00	n/a
2023	$0	-$64.8K	-$64.8K	$0.00	n/a
2022	$0	-$3.2M	-$3.2M	$0.00	n/a
2021	$0	-$14.7K	-$14.7K	$0.00	n/a
2020	n/a	-$8.9K	-$8.9K	$0.00	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 6, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 7, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Nika Pharmaceuticals, Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 10, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS $0.00 versus $0.00.
May 12, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS $0.00 versus $0.00.
March 25, 2026
Annual report 10-K · period to December 31, 2025Diluted EPS $0.00 versus $0.00.
November 7, 2025
Quarterly report 10-Q · period to September 30, 2025Diluted EPS $0.00 versus $0.00.
August 14, 2025
Quarterly report 10-Q · period to June 30, 2025Diluted EPS was $0.00.
May 13, 2025
Quarterly report 10-Q · period to March 31, 2025Diluted EPS was $0.00.
March 31, 2025
Annual report 10-K · period to December 31, 2024Diluted EPS $0.00 versus $0.00.
November 12, 2024
Quarterly report 10-Q · period to September 30, 2024Diluted EPS was $0.00.
November 1, 2024
Quarterly report (amended) 10-Q/A · period to June 30, 2024
October 16, 2024
Auditor change 8-K

Recent insider filings (Forms 3, 4 and 144): 4, the latest on April 16, 2025. Insider transactions on SEC

All filings on SEC EDGAR

Questions about NIKA

What does Nika Pharmaceuticals, Inc do?

Nika Pharmaceuticals, Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker NIKA.

Is Nika Pharmaceuticals, Inc profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $78.1K.

When did Nika Pharmaceuticals, Inc last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare NIKA with

Compare NIKA with any company

Follow NIKA

Get an email when Nika Pharmaceuticals, Inc files with the SEC: results, executive changes, material agreements and annual reports.

Follow NIKA: get an email when it files

Where the numbers come from

Financial figures are the values Nika Pharmaceuticals, Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.